Micah Rappazzo concentrates his practice in intellectual property, with a particular focus on life sciences matters.
Drawing on a background in biomedical engineering, Micah has advised on all phases of IP litigation. He also has experience performing IP due diligence for pre-litigation assessments and in support of corporate transactions.
- A pharmaceutical company in Hatch-Waxman litigation arising from submission of an ANDA seeking approval to manufacture and sell a generic version of Victoza®.
- A pharmaceutical company in Hatch-Waxman litigation arising from submission of an ANDA seeking approval to manufacture and sell a generic version of Neupro®.
- A pharmaceutical company in multiple inter partes review proceedings related to the submission of an aBLA seeking approval to manufacture and sell a biosimilar version of Herceptin®.
- A biopharmaceutical company in district court litigation over attorneys’ fees, where the court found the underlying merits “exceptional” under the Patent Act and awarded the client millions of dollars in attorneys’ fees and costs.
- A pharmaceutical company in a multi-billion dollar transaction involving its acquisition of another company’s patent and product portfolio, including valuable platform technologies in a variety of therapeutic areas.
Admitted To Practice
U.S. Patent and Trademark Office
J.D., Emory University School of Law, 2017
B.S.E., Arizona State University, 2014